TABLE III.
Product profiles
| Attribute | Characteristics similar to those of | |||
|---|---|---|---|---|
|
| ||||
| Denosumab20 | Zoledronic acid21 | Clodronate22 | Pamidronate23 | |
| Time until first SRE (months) | 27.7 | 19.5 | 15–20 (assumed 17.5) | 10.9 |
| Time until worsening of pain (months) | 5.9 | 5.6 | 3 | 0.03 to several (assumed 3) |
| Risk of ONJ each year (%) | 1.8 | 1.3 | Yes, but value not stated (assumed 1) | Yes, but value not stated (assumed 1) |
| Risk of renal impairment each year (%) | 0 | 9.3 | Yes, but value not stated (assumed 5) | 8.1 |
| Mode of administration | Injection every 4 weeks | 15-Minute infusion every 4 weeks | Daily oral tablet | 120-Minute infusion every 4 weeks |
SRE = skeletal-related event; ONJ = osteonecrosis of the jaw.